Diagnosis and Treatment of Lupus Nephritis: a Summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2023 Sep 4

PMID 37664575

Authors

Jorge E Rojas-Rivera

Clara Garcia-Carro

Ana I Avila

Mar Espino

Mario Espinosa

Gema Fernandez-Juarez

Xavier Fulladosa

Marian Goicoechea

Manuel Macia

Enrique Morales

Luis F Quintana

Manuel Praga

Affiliations

Soon will be listed here.

Abstract

Lupus nephritis (LN) is the most frequent serious manifestation of patients with systemic lupus erythematosus (SLE). Up to 60% of SLE patients develop LN, which has a significant impact on their quality of life and prognosis. Recent advances have improved the diagnostic approach to LN, and new drugs that block specific pathways and kidney damage progression have been developed. Several randomized and well-powered clinical trials have confirmed the efficacy of these agents in terms of proteinuria remission and preservation of kidney function in the medium and long term, with an acceptable safety profile and good tolerance. The combination of different therapies allows for reduction of the dose and duration of corticosteroids and other potentially toxic therapies and leads to an increase in the number of patients achieving complete remission of the disease. This consensus document carried out by the Spanish Group for the Study of Glomerular Diseases (GLOSEN) provides practical and updated recommendations, based on the best available evidence and clinical expertise of participating nephrologists.

Citing Articles

Comparison of Histomorphological Indices Between Adult and Pediatric Patients in Response to Induction Therapy.

Murugesan V, Mathew A, Rajasekharan Nair R, Kurian G, Paul Polachirakal Z, Sreedharan S Cureus. 2024; 16(8):e66673.

PMID: 39262553 PMC: 11390143. DOI: 10.7759/cureus.66673.

Lupus Nephritis from Pathogenesis to New Therapies: An Update.

Roveta A, Parodi E, Brezzi B, Tunesi F, Zanetti V, Merlotti G Int J Mol Sci. 2024; 25(16).

PMID: 39201667 PMC: 11354900. DOI: 10.3390/ijms25168981.

Unmasking Focal Segmental Glomerulosclerosis in a Patient With Lupus Nephritis.

Acob T, Jumaah O, Kakhktsyan T, Hakobyan K, Prabhakaran S Cureus. 2024; 16(6):e63008.

PMID: 39050286 PMC: 11268982. DOI: 10.7759/cureus.63008.

Factors influencing self-management behaviors in persons with lupus nephritis: A cross-sectional study.

Hanrop S, Sriyuktasuth A, Pongthavornkamol K, Piaseu N, Chawanasuntorapoj R Belitung Nurs J. 2024; 10(3):351-359.

PMID: 38947300 PMC: 11211741. DOI: 10.33546/bnj.3257.

Unraveling Complexity: A Case of Possible Overlapping Between Mixed Connective Tissue Disease and Systemic Lupus Erythematosus With Renal Involvement.

Smith Jr D, Reid D, Mascio A, Noel B, Giangreco M Cureus. 2024; 16(5):e60839.

PMID: 38910663 PMC: 11191410. DOI: 10.7759/cureus.60839.

References

Hu W, Chen Y, Bao H, Liu Z, Wang S, Zhang H . Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus. 2015; 24(10):1067-75. DOI: 10.1177/0961203315578766. View

Almaani S, Meara A, Rovin B . Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016; 12(5):825-835. PMC: 5477208. DOI: 10.2215/CJN.05780616. View

Contis A, Vanquaethem H, Truchetet M, Couzi L, Rigothier C, Richez C . Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol. 2016; 35(2):517-22. DOI: 10.1007/s10067-015-3166-9. View

Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D . Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017; 37(8):1249-1255. DOI: 10.1007/s00296-017-3686-5. View

Park M, Caselman N, Ulmer S, Weitz I . Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018; 2(16):2090-2094. PMC: 6113612. DOI: 10.1182/bloodadvances.2018019596. View

Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G . Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004; 43(1):28-36. DOI: 10.1053/j.ajkd.2003.09.011. View

Narvaez J, Ricse M, Goma M, Mitjavila F, Fulladosa X, Capdevila O . The value of repeat biopsy in lupus nephritis flares. Medicine (Baltimore). 2017; 96(24):e7099. PMC: 5478313. DOI: 10.1097/MD.0000000000007099. View

Sengul Samanci N, Ayer M, Ergen A, Ozturk S . An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report. Transfus Apher Sci. 2015; 52(3):314-6. DOI: 10.1016/j.transci.2015.01.006. View

Ugarte A, Danza A, Ruiz-Irastorza G . Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018; 30(5):482-489. DOI: 10.1097/BOR.0000000000000527. View

10.

Ghaussy N, Sibbitt Jr W, Bankhurst A, Qualls C . Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol. 2003; 30(6):1215-21. View

11.

Reid V, Mullan A, Erwig L . Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep. 2013; 2013. PMC: 3794262. DOI: 10.1136/bcr-2013-200980. View

12.

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

13.

Uribe A, Vila L, McGwin Jr G, Sanchez M, Reveille J, Alarcon G . The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004; 31(10):1934-40. View

14.

Tamirou F, DCruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C . Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2015; 75(3):526-31. PMC: 4789692. DOI: 10.1136/annrheumdis-2014-206897. View

15.

Weidenbusch M, Bai Y, Eder J, Anders H . Refractory lupus nephritis: a survey. Lupus. 2019; 28(4):455-464. DOI: 10.1177/0961203319828516. View

16.

Dorner T, Furie R . Novel paradigms in systemic lupus erythematosus. Lancet. 2019; 393(10188):2344-2358. DOI: 10.1016/S0140-6736(19)30546-X. View

17.

Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A . The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore). 2004; 83(1):1-17. DOI: 10.1097/01.md.0000104742.42401.e2. View

18.

Reich H, Gladman D, Urowitz M, Bargman J, Hladunewich M, Lou W . Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int. 2011; 79(8):914-20. DOI: 10.1038/ki.2010.525. View

19.

Rovin B, Caster D, Cattran D, Gibson K, Hogan J, Moeller M . Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(2):281-295. DOI: 10.1016/j.kint.2018.11.008. View

20.

Contreras G, Pardo V, LeClercq B, Lenz O, Tozman E, ONan P . Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350(10):971-80. DOI: 10.1056/NEJMoa031855. View